Compare Inovio Pharmaceuticals Inc (INO) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Wells Fargo & Co — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Wells Fargo & Co trades at $83.55 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 2211.1× Inovio Pharmaceuticals Inc's market cap, and Wells Fargo & Co pays a 2.44% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Wells Fargo & Co for 88 Days on average.
| INO | WFC | |
|---|---|---|
Market Cap | $112.19M | $248.06B |
Volume | 3,201,278 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $2.60 | $96.40 |
52-Week Low | $0.66 | $73.42 |
Typical Hold Time | 43 Days | 88 Days |
Enterprise Value | $83.51M | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Wells Fargo (WFC) trades at $82.06, up 2.24% today, with a bearish technical signal but strong fundamentals including a P/E of 11.92 and net income margin of 25.97%. Recent earnings show a beat in Q2 2026 but misses in prior quarters. The company's credit rating was upgraded to 'A-' by S&P on October 1, 2026, reflecting improved risk management. Cash flow trends indicate volatility, with 2025 showing negative operating cash flow but positive projections for 2026.
The outlook for WFC is mixed; analyst consensus targets $99.13 with 47% buy ratings, suggesting upside potential, but technical indicators and recent earnings misses pose near-term risks. Key opportunities include dividend stability and rate hike benefits, while risks involve cash flow volatility and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
